Guardian Pharmacy Services GRDN Unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures

Unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures at other companies

American International GroupAIG

$27M—

Keysight TechnologiesKEYS

$163M+31.5%

Rockwell AutomationROK

$76M-24.8%

PPG IndustriesPPG

$126.62-9.0%

U.S. BancorpUSB

$177M+4.7%

eBayEBAY

$902M+11.4%

Other financials

Income statement

See full

Revenue$336.6M+2.2%

Gross profit$76.3M+18.6%

Operating income$17.7M+35.9%

Net income$13.3M+40.7%

EPS (diluted)$0.21+40.0%

Balance sheet

See full

Cash & equivalents$64.9M+364%

Total debt$36.9M+29.6%

Total equity$232.4M+42.4%

Total assets$426.9M+27.8%

Cash flow

See full

Operating cash flow$6.1M-65.5%

CapEx$495.0K-78.0%

Free cash flow$34.1M+69.8%

Valuation

See full

Market cap$2.48B+80.1%

Enterprise value$2.45B+76.1%

P/E46.8×—

P/S1.7×+0.6×

Profitability

See full

Gross margin20.9%+1.1pp

Operating margin5.3%—

Net margin3.6%+2.1pp

Returns & leverage

See full

Return on equity26.8%—

Debt / equity0.2×0.0×

Current ratio1.5×+0.3×

Where this comes from

Reported directly by Guardian Pharmacy Services in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions.

The official record: Guardian Pharmacy Services’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Guardian Pharmacy Services's unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Guardian Pharmacy Services's unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures?: Guardian Pharmacy Services (GRDN) reported unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures of $28.66M in Q1 2026.